您的购物车当前为空
Labradimil is a bradykinin B2 receptor agonist. Labradimil increases the permeability of human brain microvascular endothelial cell monolayers. Labradimil enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain. Labradimil increases carboplatin levels in brain tumors after pretreatment with dexamethasone.
别名 RMP-7, Receptor-mediated permeabiliser-7, DRG-0182, DRG0182, DRG 0182, ALK-01-040
Labradimil is a bradykinin B2 receptor agonist. Labradimil increases the permeability of human brain microvascular endothelial cell monolayers. Labradimil enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain. Labradimil increases carboplatin levels in brain tumors after pretreatment with dexamethasone.

| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 mg | ¥ 10,600 | 待询 | |
| 50 mg | ¥ 13,800 | 待询 | |
| 100 mg | ¥ 17,500 | 待询 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
| 产品描述 | Labradimil is a bradykinin B2 receptor agonist. Labradimil increases the permeability of human brain microvascular endothelial cell monolayers. Labradimil enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain. Labradimil increases carboplatin levels in brain tumors after pretreatment with dexamethasone. |
| 靶点活性 | Bradykinin receptor B2:0.54 nM (Ki) |
| 别名 | RMP-7, Receptor-mediated permeabiliser-7, DRG-0182, DRG0182, DRG 0182, ALK-01-040 |
| 分子量 | 1098.29 |
| 分子式 | C49H75N15O12S |
| CAS No. | 159768-75-9 |
| Smiles | COc1ccc(C[C@@H](CN[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](Cc2cccs2)NC(=O)CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H]2CCCN2C(=O)[C@@H](N)CCCNC(N)=N)cc1 |
| 密度 | 1.53 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 |
对于不同动物的给药剂量换算,您也可以参考 更多